Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cancer Immunology, Immunotherapy
Published in: Cancer Immunology, Immunotherapy 2/2023

11-08-2022 | Kidney Cancer | Original Article

Soluble CD163: a novel independent prognostic biomarker in patients with metastatic renal cell carcinoma

Authors: Kasper Munch Lauridsen, Marianne Hokland, Sinan Al-Karradi, Holger Jon Møller, Frede Donskov, Morten Nørgaard Andersen

Published in: Cancer Immunology, Immunotherapy | Issue 2/2023

Login to get access

Abstract

The hemoglobin-haptoglobin scavenger receptor CD163 is present in both a membrane-bound form on monocytes and macrophages (mCD163) and a shed soluble circulating form (sCD163). CD163 is a well-described marker of M2-like tumor-associated macrophages, but in patients with metastatic renal cell carcinoma (mRCC), monocyte mCD163 and serum sCD163 levels have not previously been investigated and associated with patient overall survival (OS). Here, we report mCD163 expression on peripheral blood monocytes, as well as sCD163 serum levels, in samples from 89 patients newly diagnosed with mRCC and 20 healthy controls. We found that in mRCC patients, compared to healthy controls, monocyte mCD163 levels were reduced (P < 0.001) whereas serum sCD163 levels were increased (P = 0.004). Moreover, an inverse correlation between mCD163 and sCD163 levels (P = 0.04) was shown. In survival analyses, intermediary levels of monocyte mCD163 were associated with longest OS, compared to both lower and higher mCD163 levels, which were both associated with worse outcomes (P < 0.01). Further, higher levels of sCD163 at diagnosis were associated with poor OS in both univariate (P < 0.001) and multivariate analysis (HR = 1.28; 95%CI 1.09–1.50, P = 0.002). Importantly, stratification by low vs. high sCD163 was able to separate patients with International Metastatic RCC Database Consortium (IMDC) intermediate risk (IMDCINT) into two subgroups with different OS (P = 0.03): IMDCINT-sCD163LOW showed survival similar to IMDCFAV patients, and IMDCINT-sCD163HIGH showed survival similar to IMDCPOOR patients. Thus, baseline sCD163 is a novel independent biomarker of OS in mRCC, and using sCD163 as an add-on biomarker may improve prognostic value for patients in the heterogenous IMDC intermediate group.
Appendix
Available only for authorised users
Literature
1.
Abe H, Kamai T (2013) Recent advances in the treatment of metastatic renal cell carcinoma. Int J Urol 20(10):944–955
2.
Ko JJ, Xie W, Kroeger N, Lee J-l, Rini B, Knox JJ et al (2015) Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study. Lancet Oncol 16(3):293–300CrossRef
3.
Bosse D, Lin X, Simantov R, Lalani AA, Derweesh I, Chang SL et al (2019) Response of primary renal cell carcinoma to systemic therapy. Eur Urol 76(6):852–860CrossRef
4.
Heng DYC, Xie W, Regan MM, Harshman LC, Bjarnason GA, Vaishampayan UN et al (2013) External validation and comparison with other models of the international metastatic renal-cell carcinoma database consortium prognostic model: a population-based study. Lancet Oncol 14(2):141–148CrossRef
5.
Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):646–674CrossRef
6.
Belgiovine C, D’Incalci M, Allavena P, Frapolli R (2016) Tumor-associated macrophages and anti-tumor therapies: complex links. Cell Mol Life Sci 73(13):2411–2424CrossRef
7.
Baird L, Terskikh A (2010) The tumor microenvironment. Adv Exp Med Biol 671:67–73CrossRef
8.
Bover LC, Cardó-Vila M, Kuniyasu A, Sun J, Rangel R, Takeya M et al (2007) A previously unrecognized protein-protein interaction between TWEAK and CD163: potential biological implications. J Immunol 178(12):8183–8194CrossRef
9.
Komohara Y, Fujiwara Y, Ohnishi K, Takeya M (2016) Tumor-associated macrophages: potential therapeutic targets for anti-cancer therapy. Adv Drug Deliv Rev 99(Pt B):180–185CrossRef
10.
Biswas SK, Mantovani A (2010) Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol 11(10):889–896CrossRef
11.
Moller HJ, Peterslund NA, Graversen JH, Moestrup SK (2002) Identification of the hemoglobin scavenger receptor/CD163 as a natural soluble protein in plasma. Blood 99(1):378–380CrossRef
12.
Moestrup S, Møller H (2004) CD163: a regulated hemoglobin scavenger receptor with a role in the anti-inflammatory response. Ann Med 36(5):347–354CrossRef
13.
Andersen MN, Etzerodt A, Graversen JH, Holthof LC, Moestrup SK, Hokland M et al (2019) STAT3 inhibition specifically in human monocytes and macrophages by CD163-targeted corosolic acid-containing liposomes. Cancer Immunol Immunother 68(3):489–502CrossRef
14.
Shen H, Liu J, Chen S, Ma X, Ying Y, Li J et al (2021) Prognostic value of tumor-associated macrophages in clear cell renal cell carcinoma: a systematic review and meta-analysis. Front Oncol 11:657318CrossRef
15.
Larionova I, Tuguzbaeva G, Ponomaryova A, Stakheyeva M, Cherdyntseva N, Pavlov V et al (2020) Tumor-associated macrophages in human breast, colorectal, lung. Ovarian Prostate Cancers Front Oncol 10:566511
16.
Nakayama T, Saito K, Kumagai J, Nakajima Y, Kijima T, Yoshida S et al (2018) Higher serum C-reactive protein level represents the immunosuppressive tumor microenvironment in patients with clear cell renal cell carcinoma. Clin Genitourin Cancer 16(6):e1151–e1158CrossRef
17.
Wang C, Hong TY, Wang YN, Peng G, Yu YW, Zhang J et al (2021) Combining UBR5 and CD163(+) tumor-associated macrophages better predicts prognosis of clear cell renal cell carcinoma patients. Cancer Immunol Immunother 70:2925–2935CrossRef
18.
Jakubzick CV, Randolph GJ, Henson PM (2017) Monocyte differentiation and antigen-presenting functions. Nat Rev Immunol 17(6):349–362CrossRef
19.
Ziegler-Heitbrock L, Hofer TP (2013) Toward a refined definition of monocyte subsets. Front Immunol 4:23CrossRef
20.
Tippett E, Cheng WJ, Westhorpe C, Cameron PU, Brew BJ, Lewin SR et al (2011) Differential expression of CD163 on monocyte subsets in healthy and HIV-1 infected individuals. PLoS ONE 6(5):e19968CrossRef
21.
Schauer D, Starlinger P, Reiter C, Jahn N, Zajc P, Buchberger E et al (2012) Intermediate monocytes but not TIE2-expressing monocytes are a sensitive diagnostic indicator for colorectal cancer. PLoS ONE 7(9):e44450CrossRef
22.
Hamm A, Prenen H, Van Delm W, Di Matteo M, Wenes M, Delamarre E et al (2016) Tumour-educated circulating monocytes are powerful candidate biomarkers for diagnosis and disease follow-up of colorectal cancer. Gut 65(6):990–1000CrossRef
23.
Goodale D, Phay C, Brown W, Gray-Statchuk L, Furlong P, Lock M et al (2009) Flow cytometric assessment of monocyte activation markers and circulating endothelial cells in patients with localized or metastatic breast cancer. Cytometry B Clin Cytom 76(2):107–117CrossRef
24.
Hou J, Wang X, Zhang M, Wang M, Gao P, Jiang Y (2019) Circulating CD14(+)CD163(+)CD209(+) M2-like monocytes are associated with the severity of infection in helicobacter pylori-positive patients. Mol Immunol 108:13–22CrossRef
25.
Zhang B, Cao M, He Y, Liu Y, Zhang G, Yang C et al (2017) Increased circulating M2-like monocytes in patients with breast cancer. Tumor Biol 39(6):101042831771157CrossRef
26.
Etzerodt A, Maniecki MB, Moller K, Moller HJ, Moestrup SK (2010) Tumor necrosis factor alpha-converting enzyme (TACE/ADAM17) mediates ectodomain shedding of the scavenger receptor CD163. J Leukoc Biol 88(6):1201–1205CrossRef
27.
28.
Jensen TO, Schmidt H, Moller HJ, Hoyer M, Maniecki MB, Sjoegren P et al (2009) Macrophage markers in serum and tumor have prognostic impact in american joint committee on cancer stage I/II melanoma. J Clin Oncol 27(20):3330–3337CrossRef
29.
No JH, Moon JM, Kim K, Kim YB (2013) Prognostic significance of serum soluble CD163 level in patients with epithelial ovarian cancer. Gynecol Obstet Invest 75(4):263–267CrossRef
30.
Andersen MN, Abildgaard N, Maniecki MB, Moller HJ, Andersen NF (2014) Monocyte/macrophage-derived soluble CD163: a novel biomarker in multiple myeloma. Eur J Haematol 93(1):41–47CrossRef
31.
Davidsson S, Huotilainen S, Carlsson J, Sundqvist P (2022) Soluble levels of CD163, PD-L1, and IL-10 in renal cell carcinoma patients. Diagnostics (Basel) 12(2):336CrossRef
32.
Donskov F, Jensen NV, Smidt-Hansen T, Brondum L, Geertsen P (2018) A randomized phase II trial of interleukin-2 and interferon-alpha plus bevacizumab versus interleukin-2 and interferon-alpha in metastatic renal-cell carcinoma (mRCC): results from the danish renal cancer group (DaRenCa) study-1. Acta Oncol 57(5):589–594CrossRef
33.
Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J (1999) Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 17(8):2530–2540CrossRef
34.
Andersen MN, Al-Karradi SN, Kragstrup TW, Hokland M (2016) Elimination of erroneous results in flow cytometry caused by antibody binding to Fc receptors on human monocytes and macrophages. Cytometry A 89(11):1001–1009CrossRef
35.
Heinzl H, Kaider A (1997) Gaining more flexibility in Cox proportional hazards regression models with cubic spline functions. Comput Meth Prog Bio 54(3):201–208CrossRef
36.
Kotecha RR, Motzer RJ, Voss MH (2019) Towards individualized therapy for metastatic renal cell carcinoma. Nat Rev Clin Oncol 16(10):621–633CrossRef
37.
Krijgsman D, De Vries NL, Andersen MN, Skovbo A, Tollenaar R, Moller HJ et al (2020) CD163 as a biomarker in colorectal cancer: the expression on circulating monocytes and tumor-associated macrophages, and the soluble form in the blood. Int J Mol Sci 21(16):5925CrossRef
38.
Kvorning SL, Nielsen MC, Andersen NF, Hokland M, Andersen MN, Moller HJ (2020) Circulating extracellular vesicle-associated CD163 and CD206 in multiple myeloma. Eur J Haematol 104:409–419CrossRef
39.
Vajavaara H, Ekeblad F, Holte H, Jorgensen J, Leivonen SK, Berglund M et al (2021) Prognostic impact of soluble CD163 in patients with diffuse large B-cell lymphoma. Haematologica 106(9):2502–2506CrossRef
40.
Kazankov K, Rode A, Simonsen K, Villadsen GE, Nicoll A, Moller HJ et al (2016) Macrophage activation marker soluble CD163 may predict disease progression in hepatocellular carcinoma. Scand J Clin Lab Invest 76(1):64–73CrossRef
41.
Sinnathamby G, Zerfass J, Hafner J, Block P, Nickens Z, Hobeika A et al (2011) ADAM metallopeptidase domain 17 (ADAM17) is naturally processed through major histocompatibility complex (MHC) class I molecules and is a potential immunotherapeutic target in breast, ovarian and prostate cancers. Clin Exp Immunol 163(3):324–332CrossRef
42.
Roemer A, Schwettmann L, Jung M, Roigas J, Kristiansen G, Schnorr D et al (2004) Increased mRNA expression of ADAMs in renal cell carcinoma and their association with clinical outcome. Oncol Rep 11(2):529–536
43.
Davis BH, Zarev PV (2005) Human monocyte CD163 expression inversely correlates with soluble CD163 plasma levels. Cytometry B Clin Cytom 63(1):16–22CrossRef
44.
Motzer R, Banchereau R, Hamidi H, Powles T, Mcdermott D, Atkins MB et al (2020) Molecular subsets in renal cancer determine outcome to checkpoint and angiogenesis blockade. Cancer Cell 38(6):803–817CrossRef
45.
D’Costa NM, Cina D, Shrestha R, Bell RH, Lin YY, Asghari H et al (2020) Identification of gene signature for treatment response to guide precision oncology in clear-cell renal cell carcinoma. Sci Rep 10(1):2026CrossRef
Metadata
Title
Soluble CD163: a novel independent prognostic biomarker in patients with metastatic renal cell carcinoma
Authors
Kasper Munch Lauridsen
Marianne Hokland
Sinan Al-Karradi
Holger Jon Møller
Frede Donskov
Morten Nørgaard Andersen
Publication date
11-08-2022
Publisher
Springer Berlin Heidelberg
Published in
Cancer Immunology, Immunotherapy / Issue 2/2023
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-022-03266-6

Other articles of this Issue 2/2023

Cancer Immunology, Immunotherapy 2/2023 Go to the issue

Original Article

A Fc-VEGF chimeric fusion enhances PD-L1 immunotherapy via inducing immune reprogramming and infiltration in the immunosuppressive tumor microenvironment

Original Article

Association of hepatitis B virus DNA levels with overall survival for advanced hepatitis B virus-related hepatocellular carcinoma under immune checkpoint inhibitor therapy

Letter to the Editors

Bloody pericardial effusion during chemotherapy with immune checkpoint inhibitors

Original Article

Preclinical development of a vaccine-based immunotherapy regimen (VBIR) that induces potent and durable T cell responses to tumor-associated self-antigens

Original Article

Pembrolizumab, radiotherapy, and an immunomodulatory five-drug cocktail in pretreated patients with persistent, recurrent, or metastatic cervical or endometrial carcinoma: Results of the phase II PRIMMO study

Original Article

Interleukin-32γ promotes macrophage-mediated chemoresistance by inducing CSF1-dependent M2 macrophage polarization in multiple myeloma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits